DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,123,174 | +0.2% | 16,619 | -3.1% | 0.33% | +0.6% |
| Q2 2023 | $4,114,080 | -6.0% | 17,142 | -1.3% | 0.32% | -15.4% |
| Q1 2023 | $4,377,935 | -6.2% | 17,370 | -1.3% | 0.38% | -17.3% |
| Q4 2022 | $4,669,003 | +1.9% | 17,591 | -0.8% | 0.46% | -25.6% |
| Q3 2022 | $4,581,000 | +0.4% | 17,736 | -1.5% | 0.62% | -12.4% |
| Q2 2022 | $4,563,000 | -15.0% | 18,000 | -1.7% | 0.71% | -3.5% |
| Q1 2022 | $5,370,000 | -17.4% | 18,305 | -7.4% | 0.74% | -46.9% |
| Q4 2021 | $6,502,000 | +12.7% | 19,762 | +4.3% | 1.39% | +63.8% |
| Q3 2021 | $5,770,000 | +19.2% | 18,954 | +5.1% | 0.85% | +18.2% |
| Q2 2021 | $4,841,000 | +19.1% | 18,038 | -0.1% | 0.72% | -22.7% |
| Q1 2021 | $4,066,000 | -4.4% | 18,065 | -5.7% | 0.93% | +26.3% |
| Q4 2020 | $4,254,000 | +0.8% | 19,152 | -2.2% | 0.73% | -10.5% |
| Q3 2020 | $4,219,000 | +23.3% | 19,592 | +1.2% | 0.82% | +15.5% |
| Q2 2020 | $3,422,000 | +23.4% | 19,352 | -3.4% | 0.71% | -7.9% |
| Q1 2020 | $2,774,000 | -8.1% | 20,042 | +1.9% | 0.77% | +14.2% |
| Q4 2019 | $3,018,000 | +4.8% | 19,661 | -1.4% | 0.67% | -2.6% |
| Q3 2019 | $2,879,000 | +25.8% | 19,933 | +24.5% | 0.69% | +23.1% |
| Q2 2019 | $2,288,000 | +1.6% | 16,006 | -6.1% | 0.56% | +0.2% |
| Q1 2019 | $2,251,000 | +28.0% | 17,051 | 0.0% | 0.56% | +14.0% |
| Q4 2018 | $1,758,000 | -10.6% | 17,051 | -5.7% | 0.49% | +122.6% |
| Q3 2018 | $1,966,000 | +14.6% | 18,091 | +4.0% | 0.22% | +11.1% |
| Q2 2018 | $1,716,000 | +0.6% | 17,391 | -0.1% | 0.20% | -1.5% |
| Q1 2018 | $1,705,000 | -25.2% | 17,413 | -29.1% | 0.20% | -21.4% |
| Q4 2017 | $2,280,000 | -9.1% | 24,563 | -15.9% | 0.26% | -13.8% |
| Q3 2017 | $2,507,000 | +3.0% | 29,223 | +1.3% | 0.30% | -1.0% |
| Q2 2017 | $2,434,000 | -2.7% | 28,846 | -1.4% | 0.30% | -4.1% |
| Q1 2017 | $2,501,000 | +9.5% | 29,246 | -0.3% | 0.31% | +3.6% |
| Q4 2016 | $2,284,000 | -1.9% | 29,346 | -1.2% | 0.30% | -2.9% |
| Q3 2016 | $2,328,000 | -21.1% | 29,696 | +1.6% | 0.31% | -23.9% |
| Q2 2016 | $2,952,000 | +9.6% | 29,225 | +2.9% | 0.41% | +9.6% |
| Q1 2016 | $2,694,000 | +2.2% | 28,395 | 0.0% | 0.37% | -1.6% |
| Q4 2015 | $2,637,000 | +11.1% | 28,395 | +1.9% | 0.38% | +4.7% |
| Q3 2015 | $2,373,000 | -3.9% | 27,853 | -3.5% | 0.36% | +26.5% |
| Q2 2015 | $2,470,000 | -2.1% | 28,858 | -2.9% | 0.29% | -7.1% |
| Q1 2015 | $2,523,000 | +5.1% | 29,723 | +6.1% | 0.31% | -16.3% |
| Q4 2014 | $2,401,000 | +88.9% | 28,010 | +67.4% | 0.37% | +85.4% |
| Q3 2014 | $1,271,000 | -3.0% | 16,733 | +0.6% | 0.20% | -1.5% |
| Q2 2014 | $1,310,000 | +10.7% | 16,633 | +5.4% | 0.20% | +6.9% |
| Q1 2014 | $1,183,000 | +2.1% | 15,775 | +5.1% | 0.19% | -1.0% |
| Q4 2013 | $1,159,000 | +11.3% | 15,010 | 0.0% | 0.19% | -4.0% |
| Q3 2013 | $1,041,000 | +10.4% | 15,010 | +0.7% | 0.20% | +15.7% |
| Q2 2013 | $943,000 | – | 14,905 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |